Giant cell arteritis-polymyalgia rheumatica spectrum disease (GPSD): Relation with neoplasms and possible role as a
Pablo Muñoz-Martínez1, Marta Domínguez-Álvaro2, Fernando Sánchez-Alonso2
1Rheumatology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Doctoral School, Catholic University of Valencia San Vicente Mártir, Valencia, Spain.
Objectives:
To determine the incidence rate of neoplasms among the GPSD population and compare it with the Spanish general population, as well as to identify its role as a paraneoplastic syndrome in terms of temporal criteria.
Methods:
An observational, single-center, longitudinal study on GPSD patients (2015-2023) was conducted. Demographic, clinical variables and neoplasms found after GPSD diagnosis (excluding metastatic events or recurrences and non-melanoma skin cancer) were collected. In order to adjust by age and sex, we performed an indirect standardization method and calculated the standardized neoplasm ratio (SNR) and standardized incidence ratio (SIR).
Results:
Among 334 patients, 16 (4.8%) developed neoplasms, with 11 diagnosed within the first two years (7 within the first year). The SNR was 4.03 (CI 95% 1.53-6.53) in women and 2.37 (CI 95% 0.47-4.27) in men. Considering the neoplasms diagnosed in the two first years, the SNR were 2.42 (CI 95% 0.484-4.356) in women and 2.11 (CI 95% 0.258-3.868) in men.
Conclusion:
We observed a high incidence rate of neoplasms in our women GPSD patients. While no statistical significance was reached in men or in cases beyond two years post-diagnosis, a tendency toward higher rates was noted. These findings emphasize the need for further research on the potential oncologic implications of GPSD.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Related Concept Videos
Abnormal Proliferation
Nephrotic Syndrome I : Introduction
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
